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Abstract
Reactive oxygen species (ROS), a by-product of cellular metabolism, damage intracellular
macromolecules and, in excess, can promote normal hematopoietic stem cell differentiation and
exhaustion1–3. However, mechanisms that regulate ROS levels in leukemia-initiating cells (LICs)
and the biological role of ROS in these cells remain largely unknown. We show here the ROSlow
subset of CD44+ cells in T-cell acute lymphoblastic leukemia (T-ALL), a malignancy of immature
T-cell progenitors, to be highly enriched in the most aggressive LICs, and that ROS are
maintained at low levels by downregulation of protein kinase C theta (PKCθ). Strikingly, primary
mouse T-ALLs lacking PKCθ show improved LIC activity whereas enforced PKCθ expression in
both mouse and human primary T-ALLs compromised LIC activity. We also demonstrate that
PKCθ is positively regulated by RUNX1, and that NOTCH1, which is frequently activated by
mutation in T-ALL4–6 and required for LIC activity in both mouse and human models7,8,
downregulates PKCθ and ROS via a novel pathway involving induction of RUNX3 and
subsequent repression of RUNX1. These results reveal key functional roles for PKCθ and ROS in
T-ALL and suggest that aggressive biological behavior in vivo could be limited by therapeutic
strategies that promote PKCθ expression/activity or ROS accumulation.
Current therapies for T-ALL achieve cure in 80% of pediatric cases, but only 40% of adults
survive beyond 5 years9. The ineffectiveness of chemotherapeutic regimens in both age
groups may be attributed to an inability to target LICs10–12 which exhibit relative
quiescence, resistance to apoptosis, expression of DNA repair enzymes and drug efflux
pumps, and localization within protective/inaccessible niches13. More efficient targeting of
LICs could thus lead to dramatic improvements in patient outcomes.
Much recent interest has focused on the role of reactive oxygen species (ROS) in normal and
malignant stem cell biology14. ROS are chemically-reactive molecules that participate in
self-propagating reactions, and if allowed to accumulate, can cause oxidative damage to
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intracellular macromolecules including DNA, proteins, and lipids15,16. Normal
hematopoietic stem cells are uniquely sensitive to ROS1–3, and some cancer stem cells that
exhibit low ROS levels lose stem activity or become non-viable when ROS levels are
increased17,18.
To address the role of ROS in T-ALL, we focused first on LICs in a well-defined mouse
model in which animals are reconstituted with syngeneic bone marrow cells transduced with
constitutively activated NOTCH1-ΔE retrovirus. This approach produces aggressive,
serially transplantable T-cell leukemias within 8–12 weeks that are highly similar to human
T-ALL19–21. Transplantation of primary NOTCH1-ΔE leukemia cells at limiting dilution
into secondary recipients revealed the LIC frequency to be 1 in ~6,100 total cells (Fig. 1a).
Using the cell-permeable indicator dye DCFDA to assess intracellular ROS levels22 in
combination with various surface markers, we noted that the CD44+ fraction contains a
subset of cells with low ROS (Fig. 1b). To determine if LIC activity was asymmetrically
distributed within this subpopulation, CD44+ROSlow, CD44+ROShigh, and CD44– subsets
were prospectively isolated by FACS and injected into immunocompetent syngeneic
(C57BL/6) and immunocompromised NOD/Scid/Il2rg−/− (NSG) recipients. Interestingly,
the CD44+ROSlow fraction showed substantially enriched LIC activity as compared to
complementary CD44+ROShigh and CD44− fractions (Fig. 1c and Supplementary Fig. 1),
and recapitulated the original tumor heterogeneity (Supplementary Fig 2). Similar findings
were observed in a second T-ALL model initiated by K-rasG12D (Fig. 1d), indicating that
enriched LIC activity within the CD44+ROSlow fraction is not confined to the NOTCH1
model.
To assess the relevance of these findings to human disease, we transplanted FACS-sorted
ROShigh vs. ROSlow subsets of human T-ALL samples into NSG recipients. These samples
had previously been expanded in NSG mice20 to obtain sufficient material for replicate
studies. CD44 was not included in the LIC sorting strategy because most of the xenograft-
expanded human samples in our collection already contain high percentages of CD44+ cells
(data not shown). Consistent with our observations in mouse models, LIC activity was
enriched in the ROSlow fraction in human leukemias (Fig. 1e). Taken together, these studies
show that LICs in both mouse and human T-ALL are characterized by low levels of ROS.
PKCθ is a critical signaling intermediate downstream of the T-cell receptor (TCR)/
preTCR23,24 and is activated in T-ALLs arising in Notch3-IC transgenic mice23. PKCθ has
also been implicated in ROS production in normal T cells25. To explore whether PKCθ
might be involved in regulating ROS levels in T-ALL cells, we first surveyed PKCθ
expression in the NOTCH1-ΔE mouse model. We noted PKCθ protein levels to vary among
primary leukemias (Fig. 2a) and that levels of PKCθ and ROS were correlated (Fig. 2b).
Moreover, T-ALLs generated from PKCθnull bone marrow24 had very low ROS levels, and
that restoration of PKCθ expression by retroviral transduction significantly increased ROS
(Fig. 2c). A survey of human T-ALL cell lines and xenograft-expanded human T-ALL
samples also revealed varying levels of PKCθ protein (Fig. 2d). Of note, retroviral PKCθ
expression in HPBALL cells (with low endogenous PKCθ) increased ROS, whereas
shRNA-mediated PKCθ knock-down in RPMI 8402 cells (with high endogenous PKCθ)
decreased ROS (Fig. 2e,f and Supplementary Fig. 3a,b). Taken together, these data support a
dominant role for PKCθ in regulating ROS levels in both mouse and human T-ALL.
We next asked whether low ROS that characterizes LIC-enriched fractions might be due to
reduced PKCθ expression. Indeed, LIC-enriched CD44+ and CD44+ROSlow fractions from
mouse leukemias exhibited significantly less PKCθ mRNA and protein than corresponding
LIC-depleted CD44− and CD44+ROShigh fractions, respectively (Fig. 2g,h and
Supplementary Fig. 3c,d). Similarly, LIC-enriched ROSlow fractions of human leukemias
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showed significantly less PKCθ than corresponding LIC-depleted ROShigh fractions (Fig.
2i,j and Supplementary Fig. 3e). These data suggest that varied expression of PKCθ
contributes to heterogeneous ROS levels and LIC activities in subpopulations of T-ALL
cells.
To address directly the role of PKCθ in regulating LIC activity, competitive transplants
were performed between PKCθnull and wild-type leukemias, the latter with either high or
low levels of endogenous PKCθ. In each case, recipient mice developed leukemias
composed predominantly of PKCθnull cells (Supplementary Fig. 4a). Of note, a minor
population of PKCθlow cells was detected in some recipients of PKCθnull vs. PKCθlow cells,
as might be expected if increasing PKCθ “dose” progressively compromised LIC activity.
Competitive transplants were also performed between isogenic PKCθRV (PKCθnull cells
transduced with retroviral PKCθ) and parental PKCθnull cells. In recipient mice, resulting
leukemias were composed nearly entirely of PKCθnull cells, consistent with enforced PKCθ
expression having compromised LIC activity (Fig. 3a,b). Importantly, PKCθRV cells
produced leukemia under non-competitive transplant conditions, excluding a non-specific
toxic effect of enforced PKCθ expression. Strikingly, lentiviral expression of a
constitutively activated form of PKCθ26 in xenograft-expanded human T-ALL cells
abrogated LIC activity (Fig. 3c and Supplementary Fig. 4b), again supporting the idea that
increasing PKCθ “dose” has increasingly dramatic negative effects on LIC activity.
The frequency of LICs in PKCθnull and wild-type leukemias was very similar, indicating
that reduced PKCθ is permissive to, but not sufficient for LIC activity (Supplementary Fig.
5). Of note, PKCθnull and wild-type leukemias exhibit similar latencies in both primary and
secondary transplant assays, and PKCθ overexpression or knock-down does not affect cell
proliferation, suggesting that proliferation or other measures of aggressiveness cannot
explain why leukemias with lower PKCθ levels prevail in vivo. Rather, these data support
the idea that PKCθ has a dominant role in determining the ability of T-ALL cells to
reconstitute/initiate disease in vivo. Of note, low PKCθ levels were also associated with
resistance to chemotherapy and radiation (Supplementary Fig. 6) which might also confer
aggressive behavior in patients.
To explore how PKCθ expression is regulated in T-ALL, we examined available microarray
data and discovered that the transcription factor RUNX1, recently described as a tumor
suppressor in T-ALL27–29, was highly correlated with PKCθ in four separate patient cohorts
totaling 264 primary samples30–33 (Fig. 4a and Supplementary Fig. 7). ChIP-Seq for
RUNX1 in the NOTCH1-mutated human T-ALL cell line CUTLL134 revealed four high
confidence RUNX1 binding sites within the PKCθ locus, one located at the proximal
promoter (associated with H3K4me3 chromatin marks) and three within putative intronic
enhancers (associated with H3K4me1 chromatin marks)35 (Fig. 4b), suggesting that RUNX1
might regulate PKCθ expression. Consistent with this idea, shRNA-mediated knock-down
of RUNX1 resulted in decreased PKCθ mRNA and protein (Fig. 4c,d). Interestingly, ChIP-
Seq for NOTCH1 in the same cells36 revealed two high confidence NOTCH1/CSL binding
sites located 30–60 kb upstream of the RUNX3 P1 promoter37 and associated with
H3K4me1 chromatin marks (Fig. 4e), suggesting that NOTCH1 might regulate RUNX3
expression. Combined with the notion that RUNX proteins can activate or repress target
gene expression38, we hypothesized that a transcriptional circuit might be active in T-ALL
cells in which NOTCH1 activates RUNX3, RUNX3 represses RUNX1, and RUNX1
activates PKCθ (Fig. 4f). In fact, RUNX3 overexpression or knock-down resulted in
reciprocal changes in RUNX1 expression, while blocking NOTCH1 by treating cells with γ-
secretase inhibitor (GSI) decreased RUNX3, increased RUNX1, and increased PKCθ (Fig.
4g,h and Supplementary Fig. 8). Dominant negative Mastermind-like-1 (DN-MAML)39
recapitulated GSI effects on RUNX3, confirming that these effects are specific to NOTCH
Giambra et al. Page 3
Nat Med. Author manuscript; available in PMC 2013 August 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
signaling. Furthermore, GSI treatment caused ROS levels to increase, a response that did not
occur in PKCθnull mouse leukemias and which was abrogated by PKCθ inhibition or
RUNX1 knock-down in human T-ALL cells (Fig. 4i and Supplementary Fig. 8). These
results thus reveal a novel mechanism connecting NOTCH1 to LIC activity though negative
regulation of PKCθ and ROS levels, and are consistent with prior studies showing that
Notch signaling promotes LIC activity7,8. Variation among individual cell lines suggests
other factors likely impinge upon components of the NOTCH1-RUNX3-RUNX1-PKCθ
transcriptional circuit; however, the overall consistent effects support the relevance of these
results.
Our findings suggest that PKCθ may play a broad role in regulating LIC activity in T-ALL.
While the identified pathway linking NOTCH1 and PKCθ is likely most relevant in cases
with activating NOTCH16 or inactivating FBW74,5 mutations, PKCθ expression may be
similarly reduced in cases with RUNX1 mutation/loss-of-function (recently reported to
occur in 4–18% of cases27–29) or elevated RUNX3 expression, or by NOTCH/RUNX-
independent mechanisms. Alternatively, cell signaling events that modulate PKCθ activity
rather than expression level per se40 may also have important effects on LIC activity.
Further studies will be required to explore the intriguing possibility that therapies which
promote PKCθ expression and/or activity may antagonize LICs and thereby improve clinical
outcomes in patients with T-ALL.
Online Methods
Mice
PKCθ (Prkcq) knock-out mice (backcrossed over 10 generations to C57BL/6) have been
described previously24. We obtained C57BL/6 (Ly5.2), B6.SJL-PtprcaPepcb/BoyJ (Ly5.1),
and NOD/Scid/Il2rg−/− (NSG) mice from in-house colonies maintained at the BC Cancer
Agency (BCCA) Animal Resource Centre. We housed all animals in specific pathogen-free
facilities according to institutional guidelines. All breeding and animal experiments were
performed under protocols approved by the University of British Columbia (UBC) Animal
Care Committee and according to guidelines of the Canadian Council on Animal Care.
Viruses
We produced high titer, replication-defective retroviral supernatants by transient transfection
of PlatE cells41, and lentivirus by transient co-transfection of 293T cells with packaging/
envelope vectors as described42. MSCV-based retroviral expression vectors encoding
constitutively active NOTCH1 (ΔE or L1601P-ΔPEST alleles) with IRES-GFP or IRES-
tNGFR cassettes for tagging of transduced cells have been described19,21,39. We constructed
similar retroviral expression vectors carrying a wild-type PKCθ cDNA. The dominant
negative Mastermind-like-1 (DN-MAML) retroviral construct encoding amino acids 13–74
of human MAML1 fused to GFP has been previously described39. We expressed RUNX3
and constitutively activated PKCθ (A148E mutation)26 cDNAs from the lentiviral vector
pRRL-cPPT/CTS-MNDU3-PGK-GFP-WPRE which is composed of the pRRLsin-18
backbone43,44, cPPT with central DNA flap45,46, MNDU3 promoter47,48, PGK-GFP marker,
and WPRE element (plasmid construction details available upon request). We cloned the
RNAi Consortium (TRC) shRNAs49 targeting PKCθ (shPKCθ-91, TRCN0000001791;
shPKCθ-92, TRCN0000001792), RUNX1 (shRUNX1-58, TRCN0000013658;
shRUNX1-59, TRCN0000013659), and RUNX3 (shRUNX3, TRCN0000235674) into
pLKO.1puro lentivector as described50. We obtained the scrambled shRNA control
(shScramble) in pLKO.1puro vector from Addgene (#1864)51. We verified all constructs by
sequencing. We isolated virally transduced cells by fluorescence activated cell sorting
(FACS) or by selection with puromycin as applicable.
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Bone Marrow Transplantation
To generate primary mouse leukemias, we transduced bone marrow cells from 5-
fluorouracil treated mice (C57BL/6 background) with retrovirus by spinoculation20. Three
days later, we injected 10,000–40,000 GFP+ or NGFR+ cells (including at least 1×105
normal bone marrow cells) into the tail vein of lethally irradiated (810 rad) C57BL/6
recipients. For serial transplantation experiments, we injected varying numbers of total or
FACS-sorted primary leukemia cells by tail vein into non-irradiated C57BL/6 or sublethally
irradiated (200 rad) NSG secondary recipient mice. We monitored all transplant recipient
mice daily for clinical signs of leukemia. We also followed leukemia engraftment and
progression in some recipients by periodic peripheral blood sampling and flow cytometric
analysis.
Human Samples
We obtained all human samples with appropriate institutional approvals (UBC/BCCA
Research Ethics Board, Institutional Review Board of the Institut Universitaire
d’Hématologie/Université Paris Diderot, Karmanos Cancer Center Institutional Review
Board, and MD Anderson Cancer Center Institutional Review Board) and informed consent
under guidelines established by the Declaration of Helsinki. We isolated mononuclear cells
from fresh bone marrow aspirate or peripheral blood samples by density gradient
centrifugation and used them directly or cryopreserved them. Subsequent analyses utilized
human-specific antibodies against CD45, CD3, CD4, and/or CD8 (eBioscience) to discern
human T-ALL blasts.
Cell Culture
All established cell lines have been reported previously6,34,52. We cultured these cell lines in
RPMI 1640 medium supplemented with 10% fetal calf serum, 1 mM sodium pyruvate, 2
mM L-glutamine, and antibiotics. We isolated primary mouse leukemia cells from the bone
marrow or spleen of moribund mice and, where indicated, cultured them briefly in vitro in
complete media as above with supplemental cytokines IL-2 and IL-7, each at 10 ng ml−1
(Peprotech). We expanded primary human T-ALL lymphoblasts as xenografts in sublethally
irradiated in NSG mice and, where indicated, cultured them briefly in vitro on MS5/MS5-
DL1 feeders7 or immobilized Ig-DL1 ligand53 as described20.
To inhibit PKCθ enzymatic activity, we treated cells in vitro with 5 µM myristoylated PKCθ
pseudosubstrate inhibitor (cat #539636, Calbiochem). To inhibit Notch signaling, we treated
cells in vitro with 1 µM γ-secretase inhibitor XXI (compound E; cat #ALX-270-415,
Alexis). To reduce ROS levels directly, we treated cells in vitro with the vitamin E-
derivative antioxidant, Trolox (Calbiochem) at 50 µM final concentration.
We achieved doxycycline-inducible expression of DN-MAML39 by lentiviral transduction
of cells with pLVX-Tet-On Advanced (Clontech, CMV-IE promoter replaced with EF1α
promoter) followed by selection in G418, then with DN-MAML in pLVX-Tight-Puro
(Clontech) followed by selection in puromycin.
Chemotherapy and Radiation Resistance Assays
To assess drug sensitivity in vitro, we treated cells with doxorubicin (5 µg ml−1 for primary
mouse leukemias, 2 µg ml−1 for human cell lines) or dexamethasone (10 µg ml−1 for primary
mouse leukemias, 100 µg ml−1 for human cell lines) and assayed 48–72 hours later. To
assess radiation sensitivity in vitro, we treated cells with X-irradiation using a single 10 Gy
dose and assayed 48–72 hours later. We measured cell viability by flow cytometry for
exclusion of propidium iodide. To assess DNA damage in vitro, we treated cells with X-
Giambra et al. Page 5
Nat Med. Author manuscript; available in PMC 2013 August 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
irradiation using a single 1 Gy dose, cultured them for 1 hour, and then analyzed them for
phospho-histone H2A.X by flow cytometry.
Flow Cytometry
We stained mouse and human leukemia cells with fluorochrome or biotin-conjugated
antibodies against CD45, CD3, CD4, CD8, and CD44 (eBioscience, Biolegend). We used
anti-hCD271 (1:50 dilution; cat #130-091, Miltenyi Biotec) to detect the retroviral NGFR
marker. We performed intracellular staining with antibodies against PKCθ (1:5 dilution; cat
#560216, BD Biosciences), RUNX3 (1:40 dilution; cat #MAB3765, R&D Systems), and
phospho-histone H2A.X (Ser139) (1:50 dilution; cat #9718, Cell Signaling) after
paraformaldehyde fixation and permeabilization with 90% ice-cold methanol (for PKCθ and
H2A.X) or saponin (for RUNX3) as specified by the manufacturer. Where applicable, we
also used fluorchrome-conjugated secondary antibodies (1:100 dilution, Biolegend). To
assess ROS levels, we stained live cells with 5-(and-6)-carboxy-2’,7’-
dichlorodihydrofluorescein diacetate (carboxy-H2-DCFDA), dihydroethidine (DHE), or
Mitosox according to the manufacturer’s instructions (Invitrogen). We measured cell
proliferation by BrdU incorporation according to the manufacturer’s instructions (BrdU kit,
BD Biosciences). We measured cell viability by propidium iodide exclusion. We performed
FACS analysis and sorting on FACS Calibur, Canto2, Vantage DiVa, and Aria2 cytometers
(BD Biosciences). We analyzed flow cytometry data using FlowJo software (TreeStar).
Quantitative PCR
We extracted total RNA after cell lysis in Trizol reagent (Invitrogen). We generated first
strand cDNA by reverse transcription with SuperScript III (Invitrogen) using a mix of
random 15-mer and anchored oligo(dT) primers, then amplified product by quantitative real-
time PCR using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) and a Bio-Rad
Chromo4 optical detector. Specific primer sequences are available upon request. We assayed
each sample in triplicate and calculated expression levels by the ΔΔCt method with
normalization to β-actin.
Western Blot and Immunofluorescence
To generate whole cell lysates, we washed cells in ice-cold phosphate-buffered saline, then
lysed them in ice-cold 50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25% sodium
deoxycholate, 150 mM sodium chloride, 1 mM sodium orthovanadate, 1 mM sodium
fluoride, 2.5 mM sodium pyrophosphate, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, and protease inhibitor cocktail (1:500 dilution; cat #539134, Calbiochem). We ran
whole cell lysates on SDS-PAGE gels and then transferred them to Hybond-ECL
membranes (Amersham). We blocked membranes with 5% nonfat dry milk, then probed
with primary antibodies against PKCθ (1:500 dilution; cat #2059, Cell Signaling), RUNX1
(1:1,000 dilution; cat #39000, Active Motif), RUNX3 (1:1,000 dilution; cat #MAB3765,
R&D), ERK2 (1:1,000 dilution; cat #sc-154, Santa Cruz), β-actin (1:6,000 dilution; cat
#A1978, Sigma), and tubulin (1:5,000 dilution; cat #MAB3408, Chemicon). We used HRP-
conjugated secondary antibodies (1:5,000–1:10,000 dilution; Jackson ImmunoLaboratories)
with enhanced chemiluminescence (cat #32106, Pierce) and detected signals by
autoradiography. We quantified band intensities using ImageJ software54.
We performed immunofluorescence on formaldehyde-fixed, methanol-permeabilized cells
from cytospin preparations using PKCθ primary antibody (1:25 dilution; cat #2059, Cell
Signaling) followed by AlexaFluor 488-conjugated goat anti-rabbit secondary antibody
(1:100 dilution; cat #A-11008, Invitrogen) and DAPI counterstaining. We acquired images
using a Zeiss Axioplan fluorescence microscope with 20X and 40X objectives.
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ChIP-Seq
We performed chromatin immunoprecipitation (ChIP) with the ChIP Assay kit (Millipore).
Briefly, we treated cells with 1% formaldehyde for 10 minutes at 37 °C, lysed them in 1%
SDS, 10 mM EDTA, 50mM Tris (pH 8.1), and sonicated them to obtain DNA fragments
from 200–600bp. We then immunoprecipitated chromatin with the following antibodies:
RUNX1 (cat #ab23980, Abcam), Notch1 (Tc)55, CSL (kind gift of Dr. Elliott Kieff),
H3K4me1 (cat #ab8895, Abcam), H3K4me3 (cat #07-745, Millipore), and H3K27me3 (cat
#07-449, Millipore). Following overnight incubation with antisera at 4 °C, we captured
immunoprecipitated chromatin with Protein A-agarose beads which we subsequently
washed and eluted bound chromatin. After reversal of cross-links, we purified DNA using
the QIAquick PCR purification kit (Qiagen). We prepared ChIP-Seq libraries according to
the Illumina ChIP DNA library preparation kit. Following addition of adaptors, we
amplified libraries by 18 cycles of PCR, size selected (150–250 bp) by electrophoresis, and
purified using a Qiagen gel extraction kit. Following quality control testing on an Agilent
2100 Bioanalyzer, we subjected the library to deep sequencing using an Illumina Genome
Analyzer II in the Harvard Medical School Biopolymers Core facility. We aligned
sequencing reads to human genome build hg19 and analyzed using CisGenome56. Mapped
reads ranged from 1 × 107 to 3.4 × 107 per library.
Microarray Data Analysis
We downloaded normalized datasets from the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/) and analyzed them using dChip software57.
Statistics
We analyzed quantitative data using GraphPad Prism 5 software. We calculated LIC
frequencies from limiting dilution transplant results as described58.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Leukemia-initiating cells (LICs) in T-ALL are characterized by low ROS
(a,c,d,e) Survival of recipient mice following transplantation with primary mouse (a,c)
NOTCH1-ΔE or (d) K-rasG12D leukemias, or (e) xenograft-expanded primary human T-
lymphoblasts. Either (a) total leukemia cells or (c–e) FACS-sorted subsets were injected by
tail vein into (a,c,d) syngeneic C57BL/6 or (e) immunodeficient NSG recipients. The
number of cells injected per mouse and number of mice injected for each cellular subset are
as indicated. The calculated LIC frequency in a is 1 in ~6,000 cells (95% CI of 1 in 2,800–
13,200 cells). Statistical significance in e was calculated by Log-rank test. Raw survival data
for all transplant experiments are summarized in Supplementary Table 1.
(b) Flow cytometric analysis of reactive oxygen species (ROS) levels by DCFDA staining in
CD44+ and CD44− subsets or total cells from a primary mouse NOTCH1-ΔE leukemia.
Data depicted are representative of multiple replicates.
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Figure 2. PKCθ dictates ROS levels and is asymmetrically distributed to LIC-depleted cell
fractions
(a) Western blot analysis of PKCθ protein expression in primary mouse NOTCH1-ΔE
leukemias from wild-type (samples 1–4) and PKCθnull (KO) backgrounds.
(b,c) Flow cytometric analysis of intracellular ROS levels by DCFDA staining in mouse
NOTCH1-ΔE leukemias with naturally varying (high vs. low) and engineered levels of
PKCθ expression (PKCθnull, knocked-out by genetic deletion; RV-PKCθ, enforced by
retroviral transduction).
(d) Western blot analysis of PKCθ protein expression in human T-ALL cell lines and
primary human T-lymphoblasts following expansion as xenografts in NSG mice (The two
samples for each of M71 and H2718 represent different mice engrafted with the same
human sample).
(e,f) Flow cytometric analysis of intracellular ROS levels by DCFDA staining in human T-
ALL cell lines with engineered levels of PKCθ expression (RV-PKCθ, enforced by
retroviral transduction; RV-empty, empty retrovirus control; shPKCθ-2 and -3, knocked-
down by two different lentiviral shRNAs; shScramble, scrambled shRNA negative control).
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(g–j) Analysis of PKCθ expression in FACS-sorted LIC-enriched (CD44+, ROSlow) vs.
LIC-depleted (CD44−, ROShigh) subsets from freshly explanted (g,h) mouse NOTCH1-ΔE
leukemias and (i,j) xenograft-expanded primary human T-ALLs. (g,i) Quantitative RT-PCR
analysis of PKCθ mRNA levels. Error bars indicate standard deviation. (h,j) Flow
cytometric analysis of PKCθ protein expression.
All data depicted in this figure are representative of multiple replicates. *, P<0.05; **,
P<0.01; ***, P<0.001 (Student's t-test); ND, not detected.
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Figure 3. Increased PKCθ expression compromises disease reconstitution in vivo
(a) Competitive transplant assay between PKCθnull and PKCθRV NOTCH1-ΔE leukemia
cells (upper arm, recipients 1–3) and non-competitive transplant of PKCθRV cells (lower
arm, recipients 4–6). 1×104 PKCθnull leukemia cells plus 1×104 PKCθRV cells (PKCθnull
leukemia cells transduced with PKCθ retrovirus), or 1×104 PKCθRV cells only were i.v.
injected into syngeneic C57BL/6 recipient mice (n = 4). All animals developed aggressive
leukemia within 3 weeks. Moribund mice were euthanized and bone marrow or spleen
analyzed by flow cytometry for PKCθnull (NGFR+GFP−) vs. PKCθRV (NGFR+GFP+)
leukemia cell content. Data depicted are representative of two replicate experiments.
(b) Western blot analysis for PKCθ protein expression in leukemias arising from
competitive (recipients 1–3) and non-competitive (recipients 4–6) transplant assays as
depicted in a.
(c) Survival of mice transplanted with human T-ALL cells which had been transduced with
constitutively activated PKCθ lentivirus. T-lymphoblasts from a xenograft-expanded human
sample with very low/non-detectable levels of endogenous PKCθ expression (F1313-2; see
western blot in Fig. 2d) were transduced with lentivirus encoding a constitutively activated
form of PKCθ (A148E; PKCθ-CA) or empty vector and FACS sorted for the viral GFP
marker. 1×104 sorted GFP+ cells were injected into each of four immunodeficient NSG
recipient mice. Animals were monitored daily for development of leukemia; moribund
animals were euthanized and disease confirmed at necropsy. Significance P-value was
calculated by Log-rank test.
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Figure 4. NOTCH1 represses PKCθ and ROS via RUNX3 and RUNX1
(a) Microarray expression profile data from primary human T-ALL samples (GSE26713).
Samples are ordered left-to-right by PKCθ expression level. Top 20 genes most correlated
with PKCθ are ordered top-to-bottom. Identified transcription factors are indicated with
Pearson’s correlation coefficient (r) in parentheses. Expression levels are normalized for
each probeset across all samples with mean = 0 and standard deviation = 1.
(b,e) ChIP-Seq reads for the indicated antibodies over human (b) PKCθ and (e) RUNX3 loci
from the human T-ALL cell line CUTLL1. Promoters (green arrows) and putative enhancers
(red arrows) are indicated.
(c) Quantitative RT-PCR analysis of PKCθ mRNA levels in human T-ALL cell lines
transduced with lentiviral shRNAs against RUNX1 or scrambled negative control
(shScramble). Error bars indicate standard deviation for assays performed in triplicate. **,
P<0.01; ***, P<0.001 (Student's t-test).
(d,g,h) Western blot analyses of PKCθ, RUNX1, and RUNX3 protein levels in CUTLL1
cells following (d) shRNA-mediated knock-down of RUNX1, (g) lentiviral overexpression
of RUNX3, and (h) Notch inhibition with γ-secretase inhibitor (GSI, 1 µM compound E).
Numbers below each panel indicate fold change after normalization to β-actin loading
control.
(f) Schematic of transcriptional circuit involving NOTCH1, RUNX3, RUNX1, and PKCθ.
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(i) Flow cytometric analysis of intracellular ROS levels by DCFDA staining in T-ALL cells
treated with GSI, myristoylated PKCθ pseudosubstrate inhibitor, and/or transduced with
RUNX1 shRNAs. Cells were treated with GSI for 3 days with PKCθ inhibitor added in the
final 24 hours before assay. Gated live events are shown. Data depicted are representative of
multiple replicates.
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